文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

First-line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age-matched general population: A pooled post hoc analysis.

作者信息

Ghia Paolo, Owen Carolyn, Allan John N, Barrientos Jacqueline C, Barr Paul M, Shi Chunxue, Szoke Anita, Abbazio Christopher, Krigsfeld Gabriel S, Burger Jan A

机构信息

Division of Experimental Oncology Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele Milan Italy.

Tom Baker Cancer Centre University of Calgary and Alberta Health Services Calgary Alberta Canada.

出版信息

Hemasphere. 2024 May 27;8(5):e74. doi: 10.1002/hem3.74. eCollection 2024 May.

DOI:10.1002/hem3.74
PMID:38803455
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11129546/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb4/11129546/9460590f9e82/HEM3-8-e74-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb4/11129546/9460590f9e82/HEM3-8-e74-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb4/11129546/9460590f9e82/HEM3-8-e74-g001.jpg

相似文献

[1]
First-line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age-matched general population: A pooled post hoc analysis.

Hemasphere. 2024-5-27

[2]
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.

JAMA Oncol. 2018-5-1

[3]
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.

Cancer Med. 2020-11

[4]
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.

Haematologica. 2018-6-7

[5]
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.

Leuk Lymphoma. 2022-6

[6]
Cost-Effectiveness of Ibrutinib as First-line Treatment for Older Patients With Chronic Lymphocytic Leukemia in Iran.

Value Health Reg Issues. 2023-11

[7]
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.

Haematologica. 2018-2-1

[8]
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.

Br J Haematol. 2022-2

[9]
Systematic Literature Review of Real-World Effectiveness Results Data for First-Line Ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.

Drugs Real World Outcomes. 2023-3

[10]
Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus Reactivation.

Acta Haematol. 2022

引用本文的文献

[1]
Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation.

Blood Neoplasia. 2024-6-10

[2]
Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLL.

Blood Adv. 2025-8-12

[3]
Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review.

Target Oncol. 2025-3

[4]
Improving Treatment Options for Patients with Double Refractory CLL.

Cancers (Basel). 2025-1-27

[5]
Chronic Lymphocytic Leukemia Care and Beyond: Navigating the Needs of Long-Term Survivors.

Cancers (Basel). 2025-1-2

本文引用的文献

[1]
Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study.

Cancers (Basel). 2023-1-13

[2]
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.

Blood. 2022-7-14

[3]
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.

Blood Adv. 2022-6-14

[4]
United States Life Tables, 2019.

Natl Vital Stat Rep. 2022-3

[5]
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial.

Haematologica. 2022-9-1

[6]
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.

Leukemia. 2019-10-18

[7]
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.

Clin Lymphoma Myeloma Leuk. 2019-7-15

[8]
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

N Engl J Med. 2019-8-1

[9]
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.

Lancet Oncol. 2018-12-3

[10]
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

N Engl J Med. 2018-12-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索